COVID-19(3) SARS-CoV-2(3) potential risk(2) COVID-19 infection(2) Nrf-2(2) mechanisms(2) Hyperinflammatory(2) IFNs(2) public health(2) acute respiratory distress syndrome(2) overcome(2) cellular(2) nucleotides(2) interferon(2) fumarate(2) antiviral activity(2) Glatiramer(2) Natalizumab(2) reinforcement(2) pathway(2) sclerosis(2) fingolimod(2) ARDS(2) raised(2) Cladribine(2) COVID-19 pandemic(2) depleting(2) Autoimmune disorders(2) Alemtuzumab(2) cytokine(2)